UnicoCell Biomed CoTPE:6794 +4.67%83 Altman Z-Score is 39.92 as of Jul. 08, 2026, which is 59% above its 10-year median of 25.13. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 923 Biotechnology companies, UnicoCell Biomed Co ranks better than 93.5% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 38.68 is strong.
UnicoCell Biomed Co has a Altman Z-Score of 39.92, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for UnicoCell Biomed Co's Altman Z-Score or its related term are showing as below:
TPE:6794'
s Altman Z-Score Range Over the Past 10 Years
Min: 7.96 Med: 25.13 Max: 42
Current: 38.68
During the past 9 years, UnicoCell Biomed Co's highest Altman Z-Score was 42.00. The lowest was 7.96. And the median was 25.13.
UnicoCell Biomed Co (TPE:6794) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
UnicoCell Biomed Co Altman Z-Score Related Terms
UnicoCell Biomed Co Altman Z-Score Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6794 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, UnicoCell Biomed Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
UnicoCell Biomed Co's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8102
+
1.4
*
-0.7613
+
3.3
*
-0.12
+
0.6
*
67.2881
+
1.0
*
0.0318
=
39.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
UnicoCell Biomed Co (TPE:6794) has a Altman Z-Score of 39.92 as of Jul. 08, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on UnicoCell Biomed Co and its competitors. This is 59% above median its historical median of 25.13. Over the past decade, UnicoCell Biomed Co's Altman Z-Score has ranged from 7.96 to 42.00. According to the industry distribution chart, UnicoCell Biomed Co ranks #60 out of 923 companies in the Biotechnology industry, placing it in the top 6.5%.
Is UnicoCell Biomed Co's Altman Z-Score too high?
UnicoCell Biomed Co's current Altman Z-Score of 39.92 is 59% above median its 10-year median of 25.13. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 42.00. The Biotechnology industry median Altman Z-Score is 2.76. UnicoCell Biomed Co's value of 39.92 is 1346.4% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #60 out of 923 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #60 out of 923 companies for Altman Z-Score. This places UnicoCell Biomed Co in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.76. UnicoCell Biomed Co's value of 39.92 is 1346.4% above this benchmark. Historically, UnicoCell Biomed Co's own Altman Z-Score has ranged from 7.96 to 42.00 over the past decade. While the company's 10-year median is 25.13 vs. the industry median of 2.76, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.76, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current Altman Z-Score of 39.92 is 1346.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current Altman Z-Score is 39.92, which is 59% above median its own 10-year median of 25.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current Altman Z-Score is 39.92, which is 59% above median its 10-year median of 25.13 and 1346.4% above the Biotechnology industry median of 2.76. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Altman Z-Score is 39.92 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
Altman Z-Score: 39.92 (59% above median its 10-year median of 25.13)
GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
Industry Position: 1346.4% above the Biotechnology median (#60 of 923)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
